Clinical Trial Update: A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver [Phase 1]

View source ↗

Summary

Phase I study examining escalating-dose isolated hepatic perfusion with melphalan for unresectable primary or metastatic liver cancers. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer
• Liver Metastases

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Liver Neoplasms, Neoplasm Metastasis | Phase 1 | Status: COMPLETED